Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer

11 juni 2026 uppdaterad av: GlaxoSmithKline

Phase 4, Open Label, Single-arm, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Primary Advanced or Recurrent Endometrial Cancer

This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).

Studieöversikt

Status

Har inte rekryterat ännu

Studietyp

Interventionell

Inskrivning (Beräknad)

100

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Participant with greater than or equals to (>=) 18 years of age, at the time of signing the informed consent.
  • Participant has histologically or cytologically proven EC with recurrent or advanced disease.
  • Participant must have primary Stage III or Stage IV disease or first recurrent EC with a low potential for cure by radiation therapy or surgery alone or in combination based on investigator's assessment.
  • Eligible for dostarlimab treatment according to the approved prescribing information and the investigator's clinical judgement.
  • Woman of childbearing potential (WOCBP) agrees to use contraceptive from screening through at least 180 days after the last dose.
  • Negative urine pregnancy test at most 24 hours prior to the first dose of study intervention.
  • Capable of giving signed informed consent.
  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

  • Participant has had greater than (>) 1 recurrence of endometrial cancer.
  • Participant has a concomitant malignancy, or participant has a prior non endometrial invasive malignancy who has been disease-free for less than (<) 3 years or who received any active treatment in the last 3 years for that malignancy.
  • Participant has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.
  • Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy.
  • Participant has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.
  • Participant has not recovered (i.e., to Grade less than or equal to [<=] 1 or to Baseline) from cytotoxic therapy induced AEs or has received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony-stimulating factor [G-CSF], Granulocyte macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin) within 21 days prior to the first dose of study drug.
  • Either the history of hypersensitivity to excipients of the study intervention or to drugs with a similar chemical structure or class of the study intervention.
  • Participant has known active hepatitis B (e.g., hepatitis B surface antigen reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid [qualitative] is detected).
  • Participant has received neo-adjuvant/adjuvant systemic anticancer therapy for primary Stage III or IV disease and:

    • has not had a recurrence or Progressive disease (PD) prior to first dose on the study, or
    • has had a recurrence or PD within 6 months of completing systemic anticancer therapy treatment prior to first dose on the study.
  • Participant has received prior therapy with an anti- Programmed death protein 1 (anti-PD-1), anti- Programmed death ligand 1 (anti-PD-L1), or Programmed death ligand 2 (anti PD L2) agent.
  • Participant has received prior anticancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days or <5 times the half life of the most recent therapy prior to study Day 1, whichever is shorter.
  • Systemic glucocorticoids for any purpose other than to manage symptoms of suspected irAEs. If medically deemed necessary (e.g., acute asthma or chronic obstructive pulmonary disease exacerbation, prophylaxis for intravenous (IV) contrast if indicated), Investigators are allowed to use their judgment to treat participants with systemic steroids. In such cases, systemic steroids should be stopped at least 24 hours prior to the next dose of study treatment.
  • Participant has received, or is scheduled to receive, a live vaccine within 30 days before first dose of study intervention, during study treatment, and for up to 180 days after receiving the last dose of study intervention.
  • Participant has a diagnosis of immunodeficiency and is receiving systemic steroid therapy (>10 milligrams [mg] daily prednisone or equivalent) within 7 days prior to the first dose of the study treatment or is receiving any other form of immunosuppressive medication.
  • Participant is currently receiving study intervention, or is enrolled or has participated in any other clinical study involving an investigational intervention and received investigational treatment or used an investigational device within 4 weeks of the first dose of dostarlimab.
  • Participant is pregnant or breastfeeding or is expecting to conceive children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of study intervention.
  • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Participants receiving Dostarlimab with Carboplatin + Paclitaxel followed by Dostarlimab Monotherapy
Participants will receive dose level 1 of dostarlimab in combination with carboplatin and paclitaxel followed by dose level 2 of dostarlimab monotherapy. Dose level 1 is the lowest dose level.
Dostarlimab kommer att administreras.
Karboplatin kommer att administreras.
Paclitaxel kommer att administreras.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Number of participants with Grade 3 or greater treatment-emergent adverse events (TEAEs) up to Week 49
Tidsram: Up to Week 49
Up to Week 49

Sekundära resultatmått

Resultatmått
Tidsram
Number of participants with Grade 3 or greater TEAEs up to Week 170
Tidsram: Up to Week 170
Up to Week 170
Number of participants with TEAEs up to Week 49
Tidsram: Up to Week 49
Up to Week 49
Number of participants with TEAEs up to Week 170
Tidsram: Up to Week 170
Up to Week 170
Number of participants with Immune-related adverse events (irAEs) up to Week 49
Tidsram: Up to Week 49
Up to Week 49
Number of participants with Immune-related adverse events (irAEs) up to Week 170
Tidsram: Up to Week 170
Up to Week 170
Number of Participants with Serious Adverse Events (SAEs), treatment related Adverse Events (AEs), treatment related SAEs, fatal AEs, non-fatal SAEs up to Week 49
Tidsram: Up to Week 49
Up to Week 49
Number of Participants with Serious Adverse Events (SAEs), treatment related Adverse Events (AEs), treatment related SAEs, fatal AEs, non-fatal SAEs up to Week 170
Tidsram: Up to Week 170
Up to Week 170
Number of Participants with AEs leading to discontinuation of treatment, AEs leading to study withdrawal and AEs leading to dose modification up to Week 49
Tidsram: Up to Week 49
Up to Week 49
Number of Participants with AEs leading to discontinuation of treatment, AEs leading to study withdrawal and AEs leading to dose modification up to Week 170
Tidsram: Up to Week 170
Up to Week 170
Change from Baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count (Giga cells per Liter) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in hematology parameters: neutrophils, lymphocytes, monocytes, eosinophils, basophils and platelet count (Giga cells per Liter) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per Liter) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in hematology parameter: Red Blood Cell (RBC) count (Trillion cells per Liter) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in hematology parameter: Hemoglobin (Hb) (Grams per Liter) up to Week 49
Tidsram: Baseline (Day 1) and up to 49
Baseline (Day 1) and up to 49
Change from Baseline in hematology parameter: Hemoglobin (Hb) (Grams per Liter) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in hematology parameter: Reticulocytes (Percentage of reticulocytes) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in hematology parameter: Reticulocytes (Percentage of reticulocytes) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters) to up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in clinical chemistry parameters: Blood urea nitrogen (BUN), glucose, calcium, sodium, and potassium levels (Millimoles per Liter) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in clinical chemistry parameters: Blood urea nitrogen (BUN), glucose, calcium, sodium, and potassium levels (Millimoles per Liter) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per Liter) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in clinical chemistry parameters: Total bilirubin, direct bilirubin and creatinine levels (Micromoles per Liter) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in clinical chemistry parameters: Total protein levels (Gram per liter) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in clinical chemistry parameters: Total protein levels (Gram per liter) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels (International units per liter) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in clinical chemistry parameters: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels (International units per liter) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in Vital signs: systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg]) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in Vital signs: systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury [mmHg]) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in Vital signs: pulse rate (Beats per minute) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in Vital signs: pulse rate (Beats per minute) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in Vital signs: body temperature (Degrees Celsius) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in Vital signs: body temperature (Degrees Celsius) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in Vital signs: respiratory rate (breaths per minute) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in Vital signs: respiratory rate (breaths per minute) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170
Change from Baseline in electrocardiogram (ECG) values: Heart rate (Beats per minute) up to Week 49
Tidsram: Baseline (Day 1) and up to Week 49
Baseline (Day 1) and up to Week 49
Change from Baseline in electrocardiogram (ECG) values: Heart rate (Beats per minute) up to Week 170
Tidsram: Baseline (Day 1) and up to Week 170
Baseline (Day 1) and up to Week 170

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: GSK Clinical Trials, GlaxoSmithKline

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

17 augusti 2026

Primärt slutförande (Beräknad)

30 augusti 2030

Avslutad studie (Beräknad)

30 augusti 2030

Studieregistreringsdatum

Först inskickad

11 juni 2026

Först inskickad som uppfyllde QC-kriterierna

11 juni 2026

Första postat (Faktisk)

17 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Tidsram för IPD-delning

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Kriterier för IPD Sharing Access

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera